A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

NCT04613674 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

441

Enrollment

INDUSTRY

Sponsor class

Conditions

Triple Negative Breast Cancer

Interventions

DRUG: Camrelizumab Plus Chemotherapy
DRUG: placebo+chemotherapy

Sponsor

Jiangsu HengRui Medicine Co., Ltd.